Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience

Documenti analoghi

• Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
  di: Christian Pfrepper, et al.
  Pubblicazione: (2024)
• The impact of emicizumab on the clinical validation of new therapies for haemophilia A
  di: Cedric Hermans, et al.
  Pubblicazione: (2024)
• Breaking barriers in haemophilia A care: One‐year real‐world experience with emicizumab prophylaxis at Civil Service Hospital, Kathmandu, Nepal
  di: Bishesh Sharma Poudyal, et al.
  Pubblicazione: (2024)
• EAHAD haemophilia gene therapy clinical outcome database (EAHAD‐GTD)
  di: Wolfgang Miesbach, et al.
  Pubblicazione: (2024)
• Evaluation of one‐stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion
  di: Sean Platton, et al.
  Pubblicazione: (2024)